Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial
Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 4011-4018
DOI: 10.1111/dom.15753 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.07.2024. Verfasst von Richard Kazibwe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Primary Prevention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health (NIH), CDC HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To assess the efficacy of aspirin use for primary prevention of cardiovascular disease (CVD) with incident atherosclerotic CVD and mortality in high‐risk type 2 diabetes. Method s In this post hoc analysis, we included participants in the ACCORD trial without CVD at baseline. The association between aspirin use and the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke or cardiovascular [CV] death) and all‐cause mortality was evaluated using Cox proportional hazard analysis adjusting for demographics, CV risk factors and comorbidities.
Results
Eligible participants ( n = 6330) were aged 62.8 ± 5.9 years at baseline, 43.8% of the participants were female, and 3026 (47.8%) used aspirin. Over a median (interquartile range) follow‐up of 4.9 (4.1–5.7) years, the number (%) of primary outcome and all‐cause mortality events in those who used aspirin (vs. those who did not), was 196 (6.5) versus 229 (6.9) and 146 (4.8) versus 147 (4.5), respectively. The adjusted hazard ratios (95% confidence interval) associated with aspirin use for the primary outcome and all‐cause mortality were 0.94 (0.77–1.14) and 1.08 (0.85–1.36), respectively.
Conclusion
In high‐risk individuals with type 2 diabetes, the use of aspirin for primary prevention was not associated with a decreased risk of incident CVD or all‐cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Cardiovascular Medicine, WellSpan Health, York, Pennsylvania, USA.
- Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- School of Graduate Studies, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Centre for Prevention of Cardiovascular Disease, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Richard Kazibwe
Förderung
- NHLBI NIH HHS
- National Institutes of Health (NIH)
- CDC HHS
- General Clinical Research Centers
- National Heart, Lung, and Blood Institute
- Centers for Disease Control and Prevention
Zitieren
APA
Kazibwe, R., Singleton, M., Bancks, M. P., Namutebi, J., Hammoud, A., Shapiro, M., & Yeboah, J. (2024). Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial. Diabetes, Obesity and Metabolism, 26(9), 4011-4018. https://doi.org/10.1111/dom.15753
Vancouver
Kazibwe R, Singleton M, Bancks MP, Namutebi J, Hammoud A, Shapiro M, et al. Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial. Diabetes, Obesity and Metabolism. 2024;26(9):4011-4018. doi:10.1111/dom.15753
BibTeX
@article{Kazibwe2024,
author = {Kazibwe, Richard and Singleton, Matthew and Bancks, Michael P and Namutebi, Juliana and Hammoud, Aziz and Shapiro, Michael and Yeboah, Joseph},
title = {Efficacy of Aspirin for primary prevention among adults with high‐risk type 2 diabetes in the ACCORD trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {9},
pages = {4011--4018},
doi = {10.1111/dom.15753}
}
EUVIMED